[1] Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, Funke R, Gage D, Harris K, Heaford A, Howland J, Kann L, Lehoczky J, LeVine R, McEwan P, McKernan K, Meldrim J, Mesirov JP, Miranda C, Morris W, Naylor J, Raymond C, Rosetti M, Santos R, Sheridan A, Sougnez C, Stange-Thomann Y, Stojanovic N, Subramanian A, Wyman D, Rogers J, Sulston J, Ainscough R, Beck S, Bentley D, Burton J, Clee C, Carter N, Coulson A, Deadman R, Deloukas P, Dunham A, Dunham I, Durbin R, French L, Grafham D, Gregory S, Hubbard T, Humphray S, Hunt A, Jones M, Lloyd C, McMurray A, Matthews L, Mercer S, Milne S, Mullikin JC, Mungall A, Plumb R, Ross M, Shownkeen R, Sims S, Waterston RH, Wilson RK, Hillier LW, McPherson JD, Marra MA, Mardis ER, Fulton LA, Chinwalla AT, Pepin KH, Gish WR, Chissoe SL, Wendl MC, Delehaunty KD, Miner TL, Delehaunty A, Kramer JB, Cook LL, Fulton RS, Johnson DL, Minx PJ, Clifton SW, Hawkins T, Branscomb E, Predki P, Richardson P, Wenning S, Slezak T, Doggett N, Cheng JF, Olsen A, Lucas S, Elkin C, Uberbacher E, Frazier M, Gibbs RA, Muzny DM, Scherer SE, Bouck JB, Sodergren EJ, Worley KC, Rives CM, Gorrell JH, Metzker ML, Naylor SL, Kucherlapati RS, Nelson DL, Weinstock GM, Sakaki Y, Fujiyama A, Hattori M, Yada T, Toyoda A, Itoh T, Kawagoe C, Watanabe H, Totoki Y, Taylor T, Weissenbach J, Heilig R, Saurin W, Artiguenave F, Brottier P, Bruls T, Pelletier E, Robert C, Wincker P, Smith DR, Doucette-Stamm L, Rubenfield M, Weinstock K, Lee HM, Dubois J, Rosenthal A, Platzer M, Nyakatura G, Taudien S, Rump A, Yang H, Yu J, Wang J, Huang G, Gu J, Hood L, Rowen L, Madan A, Qin S, Davis RW, Federspiel NA, Abola AP, Proctor MJ, Myers RM, Schmutz J, Dickson M, Grimwood J, Cox DR, Olson MV, Kaul R, Raymond C, Shimizu N, Kawasaki K, Minoshima S, Evans GA, Athanasiou M, Schultz R, Roe BA, Chen F, Pan H, Ramser J, Lehrach H, Reinhardt R, McCombie WR, de la Bastide M, Dedhia N, Blöcker H, Hornischer K, Nordsiek G, Agarwala R, Aravind L, Bailey JA, Bateman A, Batzoglou S, Birney E, Bork P, Brown DG, Burge CB, Cerutti L, Chen HC, Church D, Clamp M, Copley RR, Doerks T, Eddy SR, Eichler EE, Furey TS, Galagan J, Gilbert JG, Harmon C, Hayashizaki Y, Haussler D, Hermjakob H, Hokamp K, Jang W, Johnson LS, Jones TA, Kasif S, Kaspryzk A, Kennedy S, Kent WJ, Kitts P, Koonin EV, Korf I, Kulp D, Lancet D, Lowe TM, McLysaght A, Mikkelsen T, Moran JV, Mulder N, Pollara VJ, Ponting CP, Schuler G, Schultz J, Slater G, Smit AF, Stupka E, Szustakowki J, Thierry-Mieg D, Thierry-Mieg J, Wagner L, Wallis J, Wheeler R, Williams A, Wolf YI, Wolfe KH, Yang SP, Yeh RF, Collins F, Guyer MS, Peterson J, Felsenfeld A, Wetterstrand KA, Patrinos A, Morgan MJ, de Jong P, Catanese JJ, Osoegawa K, Shizuya H, Choi S, Chen YJ, Szustakowki J, International Human Genome Sequencing Consortium., “Initial sequencing and analysis of the human genome.” Nature, vol. 409, no. 6822, pp. 860–921, 2001.
[2] Dancey JE, Bedard PL, Onetto N, Hudson TJ, “The genetic basis for cancer treatment decisions.” Cell, vol. 148, no. 3, pp. 409–420, 2012.
[3] Vogelstein B, Kinzler KW, “The Path to Cancer --Three Strikes and You’re Out.” N. Engl. J. Med., vol. 373, no. 20, pp. 1895–1898, 2015.
[4] Walsh MF, Ritter DI, Kesserwan C, Sonkin D, Chakravarty D, Chao E, Ghosh R, Kemel Y, Wu G, Lee K, Kulkarni S, Hedges D, Mandelker D, Ceyhan-Birsoy O, Luo M, Drazer M, Zhang L, Offit K, Plon SE, “Integrating somatic variant data and biomarkers for germline variant classification in cancer predisposition genes.” Hum. Mutat., vol. 39, no. 11, pp. 1542–1552, 2018.
[5] König IR, Fuchs O, Hansen G, von Mutius E, Kopp MV, “What is precision medicine?” Eur. Respir. J., vol. 50, no. 4, 1700391, 2017.
[6] Beckmann JS, Lew D, “Reconciling evidence-based medicine and precision medicine in the era of big data: challenges and opportunities.” Genome Med., vol. 8, no. 1, pp. 134-145, 2016.
[7] Yohe S, Thyagarajan B, “Review of Clinical Next-Generation Sequencing.” Arch. Pathol. Lab. Med., vol. 141, no. 11, pp. 1544–1557, 2017.
[8] Morganti S, Tarantino P, Ferraro E, D'Amico P, Viale G, Trapani D, Duso BA, Curigliano G, “Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life.” Crit. Rev. Oncol. Hematol., vol. 133, pp. 171–182, 2019.
[9] Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, Tsimberidou AM, Vnencak-Jones CL, Wolff DJ, Younes A, Nikiforova MN, “Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer A Joint Consensus Recommendation of the Association for Molecular Pathology , American Society of Clinical Oncology , and College of American Pathologists.” J. Mol. Diagnostics, vol. 19, no. 1, pp. 4–23, 2017.
[10] Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, Pacey S, Baird R, Rosenfeld N, “Liquid biopsies come of age: towards implementation of circulating tumour DNA.” Nat. Rev. Cancer, vol. 17, no. 4, pp. 223–238, 2017.
[11] Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M, “Neoplastic characteristics of the DNA found in the plasma of cancer patients.” Oncology, vol. 46, no. 5, pp. 318–322, 1989.
[12] Leon SA, Shapiro B, Sklaroff DM, Yaros MJ, “Free DNA in the Serum of Cancer Patients and the Effect of Therapy Free DNA in the Serum of Cancer Patients and the Effect of Therapy.” Cancer Res, vol. 37, no. 3. pp. 646–650, 1977.
[13] Sato KA, Hachiya T, Iwaya T, Kume K, Matsuo T, Kawasaki K, Abiko Y, Akasaka R, Matsumoto T, Otsuka K, Nishizuka SS, “Individualized mutation detection in circulating tumor DNA for monitoring colorectal tumor burden using a cancer-associated gene sequencing panel.” PLoS One, vol. 11, no. 1, pp. 1–15, 2016.
[14] Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, Kinzler KW, Vogelstein B, Diaz LA Jr, “Circulating mutant DNA to assess tumor dynamics.” Nat. Med., vol. 14, no. 9, pp. 985–990, 2008.
[15] Li C, Jia R, Liu H, Zhang B, Wang C, “EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors.” Diagn. Pathol., vol. 13, no. 1, pp. 49-55, 2018.
[16] Shayegi N, Kramer M, Bornhäuser M, Schaich M, Schetelig J, Platzbecker U, Röllig C, Heiderich C, Landt O, Ehninger G, Thiede C; Study Alliance Leukemia (SAL), “The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML.” Blood, vol. 122, no. 1, pp. 83–92, 2013.
[17] Zeijlemaker W, Kelder A, Oussoren-Brockhoff YJ, Scholten WJ, Snel AN, Veldhuizen D, Cloos J, Ossenkoppele GJ, Schuurhuis GJ, “Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia.” Leukemia, vol. 30, no. 3, pp. 708–715, 2016.
[18] Hocking J, Mithraprabhu S, Kalff A, Spencer A, “Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignancies.,” Cancer Biol. Med., vol. 13, no. 2, pp. 215–25, 2016.
[19] Campana D, Leung W, “Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation,” Br. J. Haematol., vol. 162, no. 2, pp. 147–161, 2013.
[20] Hantel A, Stock W, Kosuri S, “Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician.,” Clin. Lymphoma. Myeloma Leuk., vol. 18, no. 10, pp. 636–647, 2018.
[21] Luu MH, Press RD, “BCR-ABL PCR testing in chronic myelogenous leukemia: molecular diagnosis for targeted cancer therapy and monitoring.” Expert Rev. Mol. Diagn., vol. 13, no. 7, pp. 749–762, 2013.
[22] van Dongen JJ, Langerak AW, Brüggemann M, Evans PA, Hummel M, Lavender FL, Delabesse E, Davi F, Schuuring E, García-Sanz R, van Krieken JH, Droese J, González D, Bastard C, White HE, Spaargaren M, González M, Parreira A, Smith JL, Morgan GJ, Kneba M, Macintyre EA, “Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.,” Leukemia, vol. 17, no. 12, pp. 2257– 2317, 2003.
[23] Phillips GL, “Allogeneic hematopoietic stem cell transplantation (HSCT) for high-risk acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS): how can we improve outcomes in the near future?” Leuk Res, vol. 36, no. 12, pp. 1490–1495, 2012.
[24] Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y, Mielcarek M, Estey EH, Appelbaum FR, Walter RB, “Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease–Based Definition of Complete Remission?” J. Clin. Oncol., pp. 329-336, 2015.
[25] Mo XD, Lv M, Huang XJ, “Preventing relapse after haematopoietic stem cell transplantation for acute leukaemia: the role of post-transplantation minimal residual disease (MRD) monitoring and MRD-directed intervention.” British Journal of Haematology, vol. 179, no. 2. pp. 184–197, 2017.
[26] Thiede C, Florek M, Bornhäuser M, Ritter M, Mohr B, Brendel C, Ehninger G, Neubauer A, “Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection.” Bone Marrow Transplant., vol. 23, no. 10, pp. 1055–1060, 1999.
[27] Martin P, “Documentation of Engraftment and Characterization of Chimerism After Hematopoietic Cell Transplantation: Stem Cell Transplantation.” In hematopoietic cell transplantation. 5th ed, Wiley Blackwell; vol. 22, pp. 272-280, 2016.
[28] Antin JH, Childs R, Filipovich AH, Giralt S, Mackinnon S, Spitzer T, Weisdorf D, “Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood an,” Biol. Blood Marrow Transplant., vol. 7, no. 9, pp. 473–485, 2001.
[29] Li J, Batcha AM, Grüning B, Mansmann UR, “An NGS Workflow Blueprint for DNA Sequencing Data and Its Application in Individualized Molecular Oncology.” Cancer Inform., vol. 14 , pp. 87–107, 2015.
[30] Riva L, Luzi L, Pelicci PG, “Genomics of Acute Myeloid Leukemia: The Next Generation.” Frontiers in Oncology, vol. 2. pp. 40-52, 2012.
[31] Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, Gundem G, Van Loo P, Martincorena I, Ganly P, Mudie L, McLaren S, O'Meara S, Raine K, Jones DR, Teague JW, Butler AP, Greaves MF, Ganser A, Döhner K, Schlenk RF, Döhner H, Campbell PJ, “Genomic Classification and Prognosis in Acute Myeloid Leukemia.” N. Engl. J. Med., vol. 374, no. 23, pp. 2209–2221, 2016.
[32] Greif PA, Eck SH, Konstandin NP, Benet-Pagès A, Ksienzyk B, Dufour A, Vetter AT, Popp HD, Lorenz-Depiereux B, Meitinger T, Bohlander SK, Strom TM, “Identification of recurring tumor-specific somatic mutations in acute myeloid leukemia by transcriptome sequencing.” Leukemia, vol. 25, p. 821-828, 2011.
[33] Vogelstein B, Kinzler KW, “Digital PCR.” Proc Natl Acad Sci, vol. 96, pp. 9236– 9241, 1999.
[34] Quan PL, Sauzade M, Brouzes E, “dPCR: A Technology Review,” Sensors, vol. 18, no. 4, pp. 1271-1298, 2018.
[35] Milbury CA, Zhong Q, Lin J, Williams M, Olson J, Link DR, Hutchison B, “Determining lower limits of detection of digital PCR assays for cancer-reated gene mutations.” Biomol. Detect. Quantif, vol. 1, no. 1, pp. 8–22, 2014.
[36] Waterhouse M, Follo M, Pfeifer D, von Bubnoff N, Duyster J, Bertz H, Finke J, “Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR.” Ann. Hematol, vol. 95, no. 5, pp. 739–744, 2016.
[37] Diaz LA Jr, Bardelli A, “Liquid Biopsies : Genotyping Circulating Tumor DNA.” J. Clin. Oncol., vol. 32, no. 6, pp. 579-586, 2017.
[38] Mithraprabhu S, Khong T, Ramachandran M, Chow A, Klarica D, Mai L, Walsh S, Broemeling D, Marziali A, Wiggin M, Hocking J, Kalff A Durie B, Spencer A, “Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma.” Leukemia, vol. 31, no.8, pp. 1695-1705, 2016.
[39] Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih lM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr, “Detection of Circulating Tumor DNA in Earlyand Late-Stage Human Malignancies.” Sci. Transl. Med., vol. 6, no. 224, pp. 224-237, 2014.
[40] Gaidzik VI, Weber D, Paschka P, Kaumanns A, Krieger S, Corbacioglu A, Krönke J, Kapp-Schwoerer S, Krämer D, Horst HA, Schmidt-Wolf I, Held G, Kündgen A, Ringhoffer M, Götze K, Kindler T, Fiedler W, Wattad M, Schlenk RF, Bullinger L, Teleanu V, Schlegelberger B, Thol F, Heuser M, Ganser A, Döhner H, Döhner K; German-Austrian Acute Myeloid Leukemia Study Group (AMLSG)., “DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia.” Leukemia, vol. 32, pp. 30-37, 2017.
[41] Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, Al Hinai A, Zeilemaker A, Erpelinck-Verschueren CAJ, Gradowska PL, Meijer R, Cloos J, Biemond BJ, Graux C, van Marwijk Kooy M, Manz MG, Pabst T, Passweg JR, Havelange V, Ossenkoppele GJ, Sanders MA, Schuurhuis GJ, Löwenberg B, Valk PJM, “Molecular Minimal Residual Disease in Acute Myeloid Leukemia.” N. Engl. J. Med., vol. 378, no. 13, pp. 1189–1199, 2018.
[42] Scherer F, Kurtz DM, Newman AM, Stehr H, Craig AF, Esfahani MS, Lovejoy AF, Chabon JJ, Klass DM, Liu CL, Zhou L, Glover C, Visser BC, Poultsides GA, Advani RH, Maeda LS, Gupta NK, Levy R, Ohgami RS, Kunder CA, Diehn M, Alizadeh AA, “Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.” Sci. Transl. Med., vol. 8, no. 364, pp. 1–12, 2016.
[43] Wood BL, Arroz M, Barnett D, DiGiuseppe J, Greig B, Kussick SJ, Oldaker T, Shenkin M, Stone E, Wallace P, “2006 Bethesda International Consensus Recommendations on the Immunophenotypic Analysis of Hematolymphoid Neoplasia by Flow Cytometry: Optimal Reagents and Reporting for the Flow Cytometric Diagnosis of Hematopoietic Neoplasia,” Cytometry. B. Clin. Cytom., vol. 72, pp. 14-22, 2007.
[44] Chase A, Grand F, Zhang JG, Blackett N, Goldman J, Gordon M, “Factors Influencing the False Positive and Negative Rates of BCR-ABL Fluorescence In Situ Hybridization.” Genes. Chromosomes Cancer, vol. 253, pp. 246–253, 1997.
[45] Balsat M, Renneville A, Thomas X, de Botton S, Caillot D, Marceau A, Lemasle E, Marolleau JP, Nibourel O, Berthon C, Raffoux E, Pigneux A, Rodriguez C, Vey N, Cayuela JM, Hayette S, Braun T, Coudé MM, Terre C, Celli-Lebras K, Dombret H, Preudhomme C, Boissel N, “Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: A study by the acute leukemia French association group.” J. Clin. Oncol., vol. 35, no. 2, pp. 185–193, 2017.
[46] Siravegna G, Marsoni S, Siena S, Bardelli A, “Integrating liquid biopsies into the management of cancer.” Nat. Rev. Clin. Oncol., vol. 14, no. 9, pp. 531-548, 2017.
[47] Yeh P, Dickinson M, Ftouni S, Hunter T, Sinha D, Wong SQ, Agarwal R, Vedururu R, Doig K, Fong CY, Blombery P, Westerman D, Dawson MA, Dawson SJ, “Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes.” Blood, vol. 129, no. 12, pp. 1685–1690, 2017.
[48] Walter RB, Gyurkocza B, Storer BE, Godwin CD, Pagel JM, Buckley SA, Sorror ML, Wood BL, Storb R, Appelbaum FR, Sandmaier BM, “Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation,” Leukemia, vol. 29, no. 1, pp. 137–144, 2015.
[49] Venton G, Courtier F, Charbonnier A, D'incan E, Saillard C, Mohty B, Mozziconacci MJ, Birnbaum D, Murati A, Vey N, Rey J, “Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms.” Am. J. Hematol., vol. 93, no. 3, pp. 330–338, 2018.
[50] Lim SJ, Lim MJ, Raptis A, Hou JZ, Farah R, Marks SM, Im A, Dorritie K, Sehgal A, Agha M, Felgar R, Lim SH, “Inferior outcome after allogeneic transplant in first remission in high-risk AML patients who required more than two cycles of induction therapy.” Am. J. Hematol., vol. 90, no. 8, pp. 715–718, 2015.
[51] Rothenberg-Thurley M, Amler S, Goerlich D, Köhnke T, Konstandin NP, Schneider S, Sauerland MC, Herold T, Hubmann M, Ksienzyk B, Zellmeier E, Bohlander SK, Subklewe M, Faldum A, Hiddemann W, Braess J, Spiekermann K, Metzeler KH, “Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.” Leukemia, vol. 32, no. 7, pp. 1598– 1608, 2018.
[52] Fiala C, Diamandis EP. “Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection”. BMC Med, vol. 16, no .1, pp. 166-176, 2018